Search Page
Save citations to file
Email citations
Email address has not been verified. Go to
My NCBI account settings
to confirm your email and then refresh this page.
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 2023 | 1 |
| 2025 | 1 |
Search Results
2 results
Results by year
Filters applied: . Clear all
Page 1
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
Lancet. 2023 Aug 12;402(10401):529-544. doi: 10.1016/S0140-6736(23)01053-X. Epub 2023 Jun 26.
Lancet. 2023.
PMID: 37385280
Clinical Trial.
Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.
Coskun T, Wu Q, Schloot NC, Haupt A, Milicevic Z, Khouli C, Harris C.
Coskun T, et al.
Lancet Diabetes Endocrinol. 2025 Aug;13(8):674-684. doi: 10.1016/S2213-8587(25)00092-0. Epub 2025 Jun 30.
Lancet Diabetes Endocrinol. 2025.
PMID: 40609566
Clinical Trial.
Item in Clipboard
Cite
Cite
ARTICLE TYPE
ARTICLE LANGUAGE
AGE
Filters on the sidebar will be reset to the default list and any currently applied filters will be cleared.